Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Correspondence
  • Published:

The regulatory landscape for actively personalized cancer immunotherapies

Nature Biotechnology volume 31, pages 880–882 (2013)Cite this article

Subjects

To the Editor:

Figure 1 shows three types of approaches towards precision tumor immunotherapy. The first type (Fig. 1a) is characterized by biomarker-based stratification of patients to be treated with one invariant drug product. Typically, patients are identified who express predictive biomarkers such as HER2 (also known as ERBB2), KRAS or epidermal growth factor receptor (EGFR) mutations. This kind of personalization is well covered by the existing regulatory framework originally intended for the development of chemical and biological drug products.

This is a preview of subscription content, access via your institution

Relevant articles

Open Access articles citing this article.

Access options

Buy this article

  • Purchase on SpringerLink
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1: Three levels of personalization in cancer immunotherapies.

References

  1. Sjoblom, T. et al. Science 314, 268–274 (2006).

    Article  Google Scholar 

  2. Gerlinger, M. et al. N. Engl. J. Med. 366, 883–892 (2012).

    Article  CAS  Google Scholar 

  3. Castle, J.C. et al. Cancer Res. 72, 1081–1091 (2012).

    Article  CAS  Google Scholar 

  4. Matsushita, H. et al. Nature 482, 400–404 (2012).

    Article  CAS  Google Scholar 

  5. Robbins, P.F. et al. Nat. Med. 19, 747–752 (2013).

    Article  CAS  Google Scholar 

  6. van Rooij, N. et al. J. Clin. Oncol. doi:10.1200/jco.2012.47.7521 (16 September 2013).

  7. Vonderheide, R.H. et al. Nat. Med. 19, 1098–1100 (2013).

    Article  CAS  Google Scholar 

  8. Terasaki, M. et al. J. Clin. Oncol. 29, 337–344 (2011).

    Article  CAS  Google Scholar 

  9. Noguchi, M. et al. Prostate 72, 834–845 (2012).

    Article  CAS  Google Scholar 

  10. Carbone, D.P. et al. J. Clin. Oncol. 23, 5099–5107 (2005).

    Article  Google Scholar 

  11. Rahma, O.E. et al. J. Transl. Med. 8, 8 (2010).

    Article  Google Scholar 

  12. Lifton, R.P. N. Engl. J. Med. 362, 1235–1236 (2010).

    Article  CAS  Google Scholar 

  13. Rammensee, H.G. et al. Immunogenetics 41, 178–228 (1995).

    Article  CAS  Google Scholar 

  14. Weinschenk, T. et al. Cancer Res. 62, 5818–5827 (2002).

    CAS  PubMed  Google Scholar 

  15. European Medicines Agency. Guideline on Strategies to Identify and Mitigate Risks for First-in-Human Clinical Trials with Investigational Medicinal Products CHMP/SWP/28367/07; http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2009/09/WC500002988.pdf (EMA, London, 2007).

Download references

Acknowledgements

U.K. participated on behalf of the CIMT Regulatory Research Group. Twincore, Centre for Experimental and Clinical Infection Research, is a joint venture between the Hannover Medical School and the Helmholtz Centre for Infection Research, Hannover, Germany.

Author information

Author notes

  1. Cedrik M Britten and Harpreet Singh-Jasuja: These authors contributed equally to this work.

  2. Thomas Hinz and Ulrich Kalinke: These authors jointly supervised this work.

Authors and Affiliations

  1. TRON - Translationale Onkologie an der Universitätsmedizin der Johannes Gutenberg-Universität Mainz gGmbH, Mainz, Germany

    Cedrik M Britten, Sebastian Kreiter & Ugur Sahin

  2. Ribological GmbH, Mainz, Germany

    Cedrik M Britten

  3. Immatics Biotechnologies GmbH, Tübingen, Germany

    Harpreet Singh-Jasuja

  4. URPhyM, NARILIS, University of Namur, Namur, Belgium

    Bruno Flamion

  5. GlaxoSmithKline, Collegeville, Pennsylvania, USA

    Axel Hoos

  6. Association for Cancer Immunotherapy, Mainz, Germany

    Christoph Huber

  7. Curevac GmbH, Tübingen, Germany

    Karl-Josef Kallen

  8. Georgia Health Sciences University Cancer Center, Augusta, Georgia, USA

    Samir N Khleif

  9. Celldex Therapeutics Inc., Needham, Massachusetts, USA

    Michaela Nielsen

  10. University of Tübingen, Tübingen, Germany

    Hans-Georg Rammensee

  11. BioNTech AG, Mainz, Germany

    Ugur Sahin

  12. Paul-Ehrlich-Institut, Langen, Germany

    Thomas Hinz

  13. Twincore, Centre for Experimental and Clinical Infection Research, Hannover, Germany

    Ulrich Kalinke

Authors
  1. Cedrik M Britten
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Harpreet Singh-Jasuja
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Bruno Flamion
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Axel Hoos
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Christoph Huber
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Karl-Josef Kallen
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Samir N Khleif
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Sebastian Kreiter
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Michaela Nielsen
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Hans-Georg Rammensee
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. Ugur Sahin
    View author publications

    You can also search for this author in PubMed Google Scholar

  12. Thomas Hinz
    View author publications

    You can also search for this author in PubMed Google Scholar

  13. Ulrich Kalinke
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Ulrich Kalinke.

Ethics declarations

Competing interests

H.S.-J. is employee and shareholder of Immatics Biotechnologies GmbH, which has a commercial interest in development of cancer immunotherapies.

C.H. is co-founder, advisor and deputy-chairman of BioNTech. BioNTech develops highly individualized mutational epitope tumor vaccines.

Supplementary information

Supplementary Text and Figures

Supplementary Note (PDF 67 kb)

Rights and permissions

Reprints and permissions

About this article

Cite this article

Britten, C., Singh-Jasuja, H., Flamion, B. et al. The regulatory landscape for actively personalized cancer immunotherapies. Nat Biotechnol 31, 880–882 (2013). https://doi.org/10.1038/nbt.2708

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/nbt.2708

This article is cited by

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing